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Abstract
Background: Recently, several studies have demonstrated that two long non-coding RNAs (lncRNAs), HULC and MALAT1,
may participate in hepatocellular carcinoma (HCC) development and progression. However, genetic variations in the two
lncRNAs and their associations with HCC susceptibility have not been reported. In this study, we hypothesized that single
nucleotide polymorphisms (SNPs) in HULC and MALAT1 may contribute to HCC risk.
Methods: We conducted a case-control study and genotyped two SNPs, rs7763881 in HULC and rs619586 in MALAT1,i n
1300 HBV positive HCC patients, 1344 HBV persistent carriers and 1344 subjects with HBV natural clearance to test the
associations between the two SNPs and susceptibility to HCC and HBV chronic infection.
Results: The variant genotypes of rs7763881 were significantly associated with decreased HCC risk in a dominant genetic
model [AC/CC vs. AA: adjusted odds ration (OR) = 0.81, 95% confidence intervals (CIs) = 0.68–0.97, P = 0.022].
Furthermore, the variant genotypes of rs619586 was associated with decreased HCC risk with a borderline significance (AG/
GG vs. AA: adjusted OR = 0.81, 95% CIs = 0.65–1.01, P = 0.057). However, no significant association was found between
the two SNPs and HBV clearance.
Conclusions: The variant genotypes of rs7763881 in HULC may contribute to decreased susceptibility to HCC in HBV
persistent carriers.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in men and the seventh in women in the world, and the
new cases of HCC in developing countries accounted for almost
85% of all patients [1]. The major risk factors for HCC include
chronic infections with the hepatitis B or C viruses, alcohol
consumption, and foodstuff contamination with aflatoxins [2–5].
Among those, the hepatitis B virus (HBV) infection is of particular
interest, for its coherent distribution with the HCC prevalence [6].
In China, although national vaccination of HBV has been carried
out for years, the infection rate of HBV is still at a high level,
approximately 5–8% in the general population [7,8]. However,
only a small fraction of HBV persistent carriers developed HCC,
suggesting genetic variation may play roles in the carcinogenesis of
HCC after HBV infection. Besides, HBV persistent infection or
HBV natural clearance may also be influenced by complex factors
of viral, host age, environmental and genetic makeups.
Based on the latest knowledge, RNA is no longer only the
bridge between DNA and protein [9]. In recent years, more
and more non-coding RNAs have been identified, including
short non-coding RNAs(microRNAs) and long non-coding
RNAs(lncRNAs). Guttman et al found over a thousand highly
conserved lncRNAs in mammals through chromatin signature
mapping [10]. However, few publications focused on the origin
and biological functions of lncRNAs than those of microRNAs.
Recently, several studies reported that lncRNAs were dysregu-
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caner development and progression were largely unknown.
HULC, short for Highly Up-regulated in Liver Cancer, is about
1.6 k nucleotide long, containing two exons but not translated
[13]. It has been identified that HULC is highly upregulated in
HCC and colorectal cancer that metastasized to livers [13,14].
MALAT1, abbreviation of Metastasis-Associated Lung Adenocar-
cinoma Transcript 1, is about 8k nucleotide long and has been
demonstrated to be dysregulated in a variety of cancers including
HCC [11,12].
Genetic variations in lncRNAs and their associations with
cancer susceptibility have rarely been reported. Recently, Jin G
et al reported the association between polymorphisms in
lncRNAs and prostate cancer [15]. In this study, we
hypothesized that single nucleotide polymorphisms (SNPs) in
HULC and MALAT1 may contribute to risk of HBV chronic
infection and HCC. To test our hypothesis, we conducted a
case-control study of 1300 HBV-positive HCC patients, 1344
HBV persistent carriers and 1344 subjects with HBV natural
clearance to assess the associations between SNPs in HULC and




This study was approved by the institutional review board of
Nanjing Medical University. The subjects’ enrollment was
described previously [16]. The newly diagnosed HCC patients
were consecutively recruited between January 2006 and Decem-
ber 2010 from the First Affiliated Hospital of Nanjing Medical
University, the Nantong Tumor Hospital, and the Qidong liver
cancer institute of Jiangsu Province, China. Each patient was
confirmed by a pathological examination and/or a-fetoprotein
elevation (.400 ng/ml) combined with imaging examination
(Magnetic resonance imaging, MRI and/or computerized tomog-
raphy, CT). Eventually, 1300 HBV positive (HCV negative) HCC
cases were included.
The controls were screened for the HBV/HCV markers from
two cities in Jiangsu Province (9720 persons from Changzhou and
48422 persons from Zhangjiagang) in 2004 and 2009, respectively.
Two groups of controls were used in the current study, one is the
HBV persistent carriers and the other is persons with HBV natural
clearance. HBV persistent carriers were positive for both HBV
surface antigen (HBsAg) and antibody to hepatitis B core antigen
(anti-HBc), negative for HCV antibody (anti-HCV). Subjects with
HBV natural clearance were negative for HBsAg and anti-HCV,
plus positive for both antibody to hepatitis B surface antigen (anti-
HBs) and anti-HBc. These people declared no hepatitis B
vaccination history. About 865 (8.9%) HBV persistent carriers
and 1759 (18.1%) subjects with HBV natural clearance were
identified from Changzhou; while 2156 (4.5%) HBV persistent
carriers and 7851 (16.2%) subjects with HBV natural clearance
were identified from Zhangjiagang. Then, we randomly selected
1344 HBV persistent carriers and 1344 HBV natural clearance
people from the two cities, which were matched to the HCC cases
on age and sex. These selected controls declared no previous
malignancy.
All participants were unrelated ethnic Han Chinese. After
written informed consent was obtained, each participant was
surveyed by a structured questionnaire to collect demographic and
exposure information. Individuals who smoked one cigarette per
day for over one year were defined as smokers, and those who
consumed one or more alcohol drinks a week for over six months
were categorized as alcohol drinkers. After the interview, about 5
milliliter venous blood sample was collected from each participant.
Serological Testing
HBsAg, anti-HBs, anti-HBc and anti-HCV were detected from
each participant’s serum by the enzyme-linked immunosorbent
assay (Kehua Bio-engineering Co., Ltd., Shanghai, China)
following the manufacturer’s instructions as described previously
[16].
SNPs Selection and Genotyping
Based on the data from Hapmap database and the criteria of
minor allele frequency (MAF) . 0.05 in Han Chinese, we found
five common SNPs (rs1328868, rs2038540, rs1328867, rs7763881
and rs1328866) in HULC, all of which are in high linkage
disequilibrium (LD). Thus, we genotyped only one SNP,
rs7763881. Similarly, there are five common SNPs (rs11227209,
rs619586, rs7927113, rs664589 and rs3200401) in MALAT1, all of
which are in one LD block and we chose rs619586 as the tagging
SNP.
Genomic DNA was extracted from a leukocyte pellet by
traditional proteinase K digestion and followed by phenol-
chloroform extraction and ethanol precipitation. SNPs rs7763881
A.C and rs619586 A.G were genotyped using the TaqMan
allelic discrimination assay on a 7900 system (Applied
Biosystems Inc.). The primers and probes for rs7763881 were as
follows:Primer:sense,5’-GGATAAAGGAATTCTGGGAAATG-
TAG-3’, antisense, 5’-GGTGCTGTGTTGTGGATTTGC-3’;
Probe: allele A, FAM-TTTGTCTGAATTGACCTAT-MGB,
alleleC,HEX-TTGTCTGACTTGACCTAT-MGB.Theprimers
and probes for rs619586 were as follows: Primer: sense, 5’-
AAAGCCCTGAACTATCACACTTTAATC-3’, antisense, 5’-
CACAAAACCCCCGGAACTT-3’;Probe:alleleA,FAM-ACTA-
TACCTACTGTCCC-MGB, allele G, HEX-CTA-
TACCTGCTGTCCC-MGB. The genotyping was performed
blindly without knowing the subjects’ case or control status. Two
blank (water) controls in each 384-well plate were used for quality
control and more than 10% samples were randomly selected to
repeat, yielding a100% concordancerate.
Statistical Analysis
Differences of demographic characteristics and genotype
frequencies of the two SNPs between the cases and controls were
calculated by the Student’s t-test (for continuous variables) and x
2
test (for categorical variables). Associations between the genotypes
and risk of HCC and HBV chronic infection were estimated by
computing odds ratios (OR) and their 95% confidence intervals
(CIs) from logistic regression analyses. Heterogeneity of associa-
tions between subgroups was assessed by the x
2 -based Q test. All
of the statistical analyses were performed with R software (version
2.13.0; The R Foundation for Statistical Computing). All tests
were two-sided and the criterion of statistical significance was set at
P , 0.05.
Results
The demographic characteristics of the 1300 HBV positive
HCC patients, 1344 HBV persistent carriers and 1344 subjects
with HBV nature clearance were summarized previously [16].
There were no significant differences in the distribution of age, sex
and smoking rate between the three groups. However, the
drinking rate was significantly higher in HCC cases than that in
controls ( both P , 0.001 for HCC cases compare to HBV
persistent carriers and clearance controls).
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98.5% for rs619589 and the observed genotype frequencies
among the controls were in HWE (P = 0.785 and 0.453 for
rs7763881 and rs619586, respectively). The genotype distribu-
tions of the two variants in HBV positive HCC cases, HBV
persistent carriers and HBV natural clearance subjects are shown
in Table 1. Compared with individuals carrying wild-type AA
genotype of rs7763881, those with AC and CC genotypes had a
decreased HCC risk with adjusted ORs of 0.79 (95% CIs =
0.66–0.95) and 0.87 (95% CIs = 0.70–1.09), respectively. The
variant AC/CC genotypes of rs7763881 significantly decreased
HCC risk by 19% (Adjusted OR = 0.81, 95% CIs = 0.68–0.97,
P = 0.022). Similarly, variant genotypes of rs6682925 were
associated with non-significant decreased HCC risk compared
with the wild-type AA genotype (adjusted OR = 0.82, 95% CIs
= 0.66–1.03 for AG; adjusted OR= 0.50, 95% CIs=0.17–1.50
for GG). The variant genotypes AG/GG of rs619586 was
associated with a decreased HCC risk with a borderline
significance (adjusted OR = 0.81, 95%CIs = 0.65–1.01, P =
0.057). However, no significant association was found between
the two SNPs and HBV clearance.
Stratified analysesofrs7763881andrs619586aresummarizedin
Table S1. The protective effect for rs7763881 was more prominent
insubjectsolderthan53yearsold(adjustedOR = 0.66,95%CIs =
0.51–0.85, P for heterogeneity test = 0.036). For rs619586, a
significant protective effect was only observed for never drinkers
(adjusted OR = 0.66, 95% CIs = 0.47–0.93, P = 0.015).
Discussion
To the best of our knowledge, this is the first study that has
provided evidence that common SNPs in lncRNAs might be
associated with HCC susceptibility. We identified rs7763881 in
HULC was significantly associated with HCC susceptibility in
HBV persistent carriers, while rs619586 was protective for non-
drinkers’ HCC risk in subgroup analysis.
Panzitt et al firstly reported that HULC was highly up-regulated
in HCC as a novel non-coding RNA [13]. In addition, siRNA-
mediated knockdown of HULC in 2 HCC cell lines resulted in
altered expression of several genes, some of which were known to
be affected in HCC, including cyclin-dependent kinase 8 and
MAP kinase interacting serine/threonine kinase 2 [13]. Further-
more, the expression of HULC was extremely tissue-specific.
Panzitt et al reported that HULC was not detected in tissues other
than liver or their associated neoplasms [13]. Matouk et al reported
that HULC was detected in colorectal carcinomas that metastasize
to livers, but not the primary colorectal carcinomas samples nor
their normal counterparts [13,14].
Based on the Hapmap database, there are five SNPs in HULC,
all of which are in high LD. Among those, rs7763881 was in
complete LD with rs1328867 (r-square = 1), which is located in
the promoter region of HULC. According to data from UCSC
(http://genome.ucsc.edu) and TFSEARCH 1.3, the wild-type
allele T of rs1328867 is predicted to bind several transcription
factors including C-Myc, while the variant allele C is not. C-Myc
plays critical roles in regulating cellular growth, differentiation and
apoptosis in both normal and neoplastic liver cells [17]. In our
study, with a relative large sample size and a power of 76%, we
found that the variant allele C of rs7763881 was associated with a
decreased HCC risk, which was consistent with the biological
relevance of HULC.
MALAT1 is highly conserved within the mammalian lineage
[18]. It is enriched in nuclear speckles in inter-phase cells and
concentrates in mitotic interchromatin granule clusters [19]. It is
co-localized with pre-mRNA-splicing factor SF2/ASF and CC3
antigen in the nuclear speckles [20]. MALAT1 was found
rearranged in renal tumors harboring the t(6;11)(p21;q13)
translocation and in a liver mesenchymal hamartoma harboring
the t(11;19)(q11;q13.4) translocation [21,22]. In this study, we
found that MALAT1 rs619586 was associated with a decreased
HCC risk with a borderline significance and was significantly
protective for HCC risk in never drinkers. The lack of
significance in the overall population might be due to the modest
association and the relative low MAF of the SNP (MAF = 0.11),
and we have only about 40% power to detect the effect in this
population with our current sample size. Larger studies are
warranted to clarify the associations between rs619586 in
MALAT1 and HCC risk.
In conclusion, the variant genotypes of rs7763881 in HULC may
contribute to decreased HCC susceptibility in HBV persistent
carriers. Association studies with diverse population and further









a P Adjusted OR
b P
rs7763881 1271 1316 1327
AA 371 29.2 333 25.3 367 27.7 1.00 1.00
AC 617 48.5 695 52.8 633 47.7 0.79(0.66–0.95) 1.20(1.00–1.45)
CC 283 22.3 288 21.9 327 24.6 0.87(0.70–1.09) 0.96(0.78–1.20)
AC/CC 900 70.8 983 74.7 960 72.3 0.81(0.68–0.97) 0.022 1.12(0.94–1.34) 0.189
rs619586 1268 1330 1330
AA 1094 86.3 1115 83.8 1116 83.9 1.00 1.00
AG 169 13.3 205 15.4 202 15.2 0.82(0.66–1.03) 1.01(0.82–1.25)
GG 5 0.4 10 0.8 12 0.9 0.50(0.17–1.50) 0.83(0.36–1.94)
AG/GG 174 13.7 215 16.2 214 16.1 0.81(0.65–1.01) 0.057 1.00(0.81–1.23) 0.989
NOTE: Logistic regression analyses adjusted for age, sex, smoking status and drinking status.
aHCC patients vs. HBV persistent carriers.
bHBV persistent carriers vs. HBV natural clearance subjects.
doi:10.1371/journal.pone.0035145.t001
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Table S1 Stratified Analysis between the two SNPs and
HCC Risk. NOTE: Logistic regression analyses adjusted for age,
sex, smoking status and drinking status in dominant genetic model
(excluded the stratified factor in each stratum).
a HCC patients
vs. HBV persistent carriers.
b P for heterogeneity.
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